News Headlines Article

‘Young blood’ Alzheimer’s treatments slapped with warning by FDA commissioner
San Francisco Business Times

Treatments offering to combat dementia and other Alzheimer’s Disease-related conditions with infusions of blood from young donors were slapped Tuesday by the Food and Drug Administration, prompting at least one company to cease treatments.

The statement by FDA Commissioner Scott Gottlieb shines a light on the work of a handful of companies operating in the Bay Area — including at least one in human clinical trials — but focuses on “establishments in several states” that offer plasma infusions from young donors to treat normal aging and memory loss from dementia, Parkinson’s disease, multiple sclerosis, post-traumatic stress disorder, heart disease and Alzheimer’s.